All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The phase I/II , open-label, multi-center, dose escalation study (NCT03008187) of the first-in-class dual PIM/Fms like tyrosine kinase (FLT3) inhibitor, SEL24, for Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) patients has been placed on full clinical hold by the US Food and Drug Administration (FDA).1 The phase I/II study aimed to determine the maximum tolerated dose of SEL24 in R/R AML patients as well as the safety and its anti-leukemic activity.
The full clinical hold decision made by the FDA comes after Selvita, the drug manufacturers, reported a suspected serious unexpected adverse reaction of a fatal stroke in a patient enrolled in one of the cohort in the dose escalation phase of the study. The patient was administered 150 mg dose of SEL24 and received four doses, after which developed a grade 4 venous thrombus in the brain with subsequent intracerebral hemorrhage. The patient was hospitalized and died four days later due to the cerebral event. The death of the patient was evaluated and it was concluded that it could possibly be related to SEL24.1
As a result of the full clinical hold, no new patients are to be enrolled into this phase I/II trial and enrolled patients are not to be administered SEL24 until the full clinical hold is lifted by the FDA. Selvita plans to “work diligently” with the FDA in order to “seek the release of the clinical hold” and will be providing the FDA with the “requested additional data and analysis on patients treated with SEL24, as well as a proposed protocol amendment.1
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox